We’re proud to share that Dr. Khaled Barakat, CEO of Thoth Biosimulations, was featured in the Spring 2025 issue of Leap Magazine for his groundbreaking discovery of Compound B — a novel small molecule immunomodulator with nanomolar potency.
The article highlights Dr. Barakat’s multidisciplinary approach, combining biophysics, computational modeling, and drug design to unlock the immune system’s potential against cancer. Compound B holds promise as a dual-action agent: overcoming immune cell anergy and inducing apoptosis in cancer cells.
This recognition reinforces Thoth’s commitment to harnessing the power of science and innovation to deliver next-generation therapeutics with precision and purpose.
You can read the full feature in Leap Magazine, published by the Alberta Cancer Foundation.
